Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06982508 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
A Phase 2 study of Antioxidant Absorption, sponsored by NewAmsterdam Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06982508 is a Phase 2 study of Antioxidant Absorption that is actively recruiting participants, run by NewAmsterdam Pharma. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06982508, a Phase 2 study of Antioxidant Absorption, is actively recruiting participants, sponsored by NewAmsterdam Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are: Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants. Participants will: Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Obicetrapib 10mg
Study Locations (1)
Florida
- Excellence Medical Research - Miami Gardens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06982508
The ClinicalTrials.gov registry entry for NCT06982508 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Antioxidant Absorption appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06982508 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06982508 about?
NCT06982508 is a clinical study titled "Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers". The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are: Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Ob...
What is the current status of trial NCT06982508?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-09-09. Estimated completion is 2026-12.
What conditions does trial NCT06982508 study?
This clinical trial studies the following conditions: Antioxidant Absorption.
What interventions are being tested in trial NCT06982508?
The interventions under investigation include: Placebo (DRUG), Obicetrapib 10mg (DRUG).
Who is sponsoring clinical trial NCT06982508?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06982508 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.